SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--VistaGen Therapeutics, Inc., welcomes news of the technological discovery reported this week that reprograms adult skin cells into human universal cells, according to H. Ralph Snodgrass, Ph.D., president and CEO. VistaGen is a platform-enabled biopharmaceutical company applying embryonic stem cell technologies to discover, develop and commercialize small molecule drugs and protein therapeutics for diabetes and neurological disorders.
